摘要
微粒(MPs)由大多数真核细胞在细胞质膜的囊泡形成后释放,作为长距离和短距离的信号的载体。来源于多重耐药肿瘤细胞的MPs携带供体细胞的分子组成,如核酸和蛋白,并通过它们的转变从而改变对药物敏感的受体细胞的活性。鉴于MPs在获得和传播多重耐药性中的重要作用,我们认为MP释放的抑制提供了一种新的治疗方法。本研究的特征是一组分子对MP生物合成途径的影响。我们发现了这些分子对MP抑制的微分效应,这些抑制的出现依赖于钙离子载体A23187激活后细胞内钙库的释放。钙蛋白酶抑制剂,PD-150606;Rho关联的选择性抑制剂,连续线圈蛋白激酶(ROCK),Y-27632;维生素B5泛硫乙胺衍生物仅在提前激活A23187时抑制MP的释放。钙蛋白酶抑制剂II在细胞不活化的情况下表现出明显的抑制作用,而维生素B5衍生物盐酸胱胺、盐酸半胱胺在任一条件下对MP抑制都无影响。相反,MDR的经典药理抑制剂,钙通道阻滞剂维拉帕米,显示在静息细胞中增加MP形成。这些结果表明了在pd-150606, Y-27632和泛硫乙胺的行动机制中钙的潜在作用。 这些分子,连同钙蛋白酶抑制剂II 表现出作为MP释放调节器的潜力和作为预防MP介导的多重耐药癌症的一种代替治疗策略的潜在候选者的权证对价。
关键词: 钙通道阻滞剂,钙蛋白酶,癌症,微粒,微粒抑制剂,微泡,多药耐药性,Rho相关激酶(ROCK)
图形摘要
Current Cancer Drug Targets
Title:Targeting Microparticle Biogenesis: A Novel Approach to the Circumvention of Cancer Multidrug Resistance
Volume: 15 Issue: 3
Author(s): Ariane Roseblade, Frederick Luk, Alison Ung and Mary Bebawy
Affiliation:
关键词: 钙通道阻滞剂,钙蛋白酶,癌症,微粒,微粒抑制剂,微泡,多药耐药性,Rho相关激酶(ROCK)
摘要: Microparticles (MPs) are released from most eukaryotic cells after the vesiculation of the plasma membrane and serve as vectors of long and short-range signaling. MPs derived from multidrug resistant (MDR) cancer cells carry molecular components of the donor cell such as nucleic acids and proteins, and can alter the activity of drug-sensitive recipient cells through the transfer of their cargo. Given the substantial role of MPs in the acquisition and dissemination of MDR, we propose that the inhibition of MP release provides a novel therapeutic approach. This study characterises the effect of a panel of molecules known to act on MP-biosynthetic pathways. We demonstrate a differential effect by these molecules on MP inhibition that appear dependent on the release of intracellular calcium stores following activation with the calcium ionophore A23187. Calpain inhibitor, PD-150606; a selective inhibitor of Rho-associated, coiled-coil containing protein kinase (ROCK), Y-27632; and the vitamin B5 derivative pantethine, inhibited MP release only upon prior activation with A23187. Calpain inhibitor II showed significant inhibition in the absence of cell activation, whereas the vitamin B5 derivatives cystamine dihydrochloride and cysteamine hydrochloride showed no effect on MP inhibition under either condition. In contrast the classical pharmacological inhibitor of MDR, the calcium channel blocker Verapamil, showed an increase in MP formation on resting cells. These results suggest a potential role for calcium in the mechanism of action for PD-150606, Y-27632 and pantethine. These molecules, together with calpain inhibitor II have shown promise as modulators of MP release and warrant consideration as potential candidates for the development of an alternative therapeutic strategy for the prevention of MP-mediated MDR in cancer.
Export Options
About this article
Cite this article as:
Ariane Roseblade, Frederick Luk, Alison Ung and Mary Bebawy , Targeting Microparticle Biogenesis: A Novel Approach to the Circumvention of Cancer Multidrug Resistance, Current Cancer Drug Targets 2015; 15 (3) . https://dx.doi.org/10.2174/1568009615666150225121508
DOI https://dx.doi.org/10.2174/1568009615666150225121508 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety The Molecular Genetics of Lentiviral Vectors - Current and Future Perspectives
Current Gene Therapy From Bacteria to Antineoplastic: Epothilones A Successful History
Anti-Cancer Agents in Medicinal Chemistry Synthetic Survey and Activity of 2'-deoxy-methanocarba Nucleosides
Current Organic Synthesis The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry Review of Selected Patents for Cancer Therapy Targeting Tumor Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Dendritic Cell Immunotherapy for Melanoma
Reviews on Recent Clinical Trials An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Shared Signaling Pathways Between Endocrine and Immune System Receptors: The Model of Gamma Chain
Current Signal Transduction Therapy microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis
Current Cancer Therapy Reviews The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer
Reviews on Recent Clinical Trials Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment
Current Pharmaceutical Design Multi-Target Inhibitors for Proteins Associated with Alzheimer: In Silico Discovery using Fragment-Based Descriptors
Current Alzheimer Research